REGENXBIO is a clinical-stage biotechnology company. Co.'s product candidates include: RGX-314, which is being developed as a gene therapy for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other additional chronic retinal conditions which cause total or partial vision loss for patients in the U.S., Europe and Japan; RGX-121, which is for the treatment of Mucopolysaccharidosis Type II; RGX-111, which is for the treatment of Mucopolysaccharidosis Type I; RGX-181, which is for the treatment of late infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease; and RGX-381, which is for the treatment of ocular manifestations of CLN2 disease. We show 35 historical shares outstanding datapoints in our RGNX shares outstanding history coverage, used to compute RGNX market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing RGNX market cap history over the course of time is important for investors
interested in comparing RGNX's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of RGNX versus a peer is one thing; comparing
RGNX market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like RGNX can fluctuate over the course of history.
With this page we aim to empower investors researching RGNX by allowing them to research the RGNX market cap history. |
Free RGNX Email Alerts:
Video: The Importance of Market Cap
